FDA Approves BridgeBio's Acoramidis Challenging Pfizer's Tafamidis with Potential of Alnylam's Amvuttra in ATTR-CM Market
BridgeBio has achieved a pivotal milestone with the FDA's approval of Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM). This approval is momentous given BridgeBio's previous setbacks, including a failed trial in 2021, and now positions Attruby against dominant market player Pfizer's tafamidis[2][3]. As a TTR stabilizer, Attruby has shown effectiveness in prolonging life and minimizing hospitalizations in clinical trials, which strengthens BridgeBio's competitive market standing[4][6]. This strategic market entry is further supported by strategic partnerships for distribution, such as with Bayer for Europe and AstraZeneca for Japan, setting the stage for a robust international market presence[2].
References
- Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
- Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy
- BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
- BridgeBio heart drug approved by FDA, setting up battle with Pfizer
- ATTR-CM Approval for BridgeBio Could Trigger Tight Race With Pfizer
- Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis
Explore Further
What unique attributes does BridgeBio's acoramidis bring to the market that distinguish it from other available treatments for ATTR-CM?
How does Alnylam's Amvuttra, as an RNAi therapeutic, compare in efficacy to traditional TTR stabilizers like Pfizer's tafamidis in treating ATTR-CM?
What strategic partnerships does BridgeBio have for distributing Attruby internationally, and how do these partnerships potentially impact their market presence?
What are the key data points from the Phase III HELIOS-B trial that support the potential approval of Alnylam's Amvuttra?
How is Pfizer responding to the increased competition in the ATTR-CM market to maintain its leadership position?